De‐Chen Lin

University of Southern California

Full Professor(heuristic)

RNA modifications and cancer · Molecular Biology

h-index52

i10-index98

Publications325

Citations15,766

Grants

12 total · 7 active

NIH #5R01DK135562-03

Modeling Pathways of Early Growth Dysregulation at the GEJ

Active

Amount: $698K
Period: 2024-05-01 → 2029-02-28
PIs: 2
Est. capacity / PI: ~3 students

Awarded at JOHNS HOPKINS UNIVERSITY

NIH #5R01DK135562-02

Modeling Pathways of Early Growth Dysregulation at the GEJ

Active

Amount: $707K
Period: 2024-05-01 → 2029-02-28
PIs: 2
Est. capacity / PI: ~3 students

Awarded at JOHNS HOPKINS UNIVERSITY

NIH #1R01DK135562-01A1

Modeling Pathways of Early Growth Dysregulation at the GEJ

Active

Amount: $731K
Period: 2024-05-01 → 2029-02-28
PIs: 2
Est. capacity / PI: ~3 students

Awarded at JOHNS HOPKINS UNIVERSITY

Student capacity is a rough estimate from remaining award size, split equally among PIs. Actual funding decisions vary.

Lab Funding Health

Find elsewhere

Institution / lab homepage Search on ResearchGate

In-Field Influence

0.0001

PageRank within Molecular Biology co-authorship network

Explore collaboration map

Admission Signals

New paper: Genome-wide variation in cell-free DNA end motif entropy predicts immunotherapy response in head and neck cancer (Journal of Clinical Investigation)2026-05-19
New preprint: ETS1 Orchestrates a Hybrid EMT Program Driving in vivo Metastasis and Immune Evasion2025-07-21
New NIH award: $698K — Modeling Pathways of Early Growth Dysregulation at the GEJ2024-05-01
New NIH award: $707K — Modeling Pathways of Early Growth Dysregulation at the GEJ2024-05-01
New NIH award: $731K — Modeling Pathways of Early Growth Dysregulation at the GEJ2024-05-01
New NIH award: $498K — Pharmacological and dietary inhibition of a novel metabolic-epigenetic crosstalk in head and neck cancer2024-03-01
New NIH award: $498K — Pharmacological and dietary inhibition of a novel metabolic-epigenetic crosstalk in head and neck cancer2024-03-01
New NIH award: $497K — Pharmacological and dietary inhibition of a novel metabolic-epigenetic crosstalk in head and neck cancer2024-03-01
New NIH award: $765K — Master regulator transcription factors promote esophageal neoplastic evolution2020-06-01

Data Freshness

Publications as of 2026-07-01
Grants as of 2026-06-30

Are you this professor?

No account needed — verify once with your ORCID iD to set recruiting status and correct your rank.

ORCID: 0000-0002-1951-367X

Career Trajectory

Research Cluster Map

Direct collaborators. Node size = influence, colour = community, dashed = past collaboration.

Potential Collaborators

Recent Publications

Last 2 years · showing 20 of 30

Genome-wide variation in cell-free DNA end motif entropy predicts immunotherapy response in head and neck cancer
Journal of Clinical Investigation · 2026-05-19
Abstract 7524: Genetically defined organoid systems uncover PIK3CA-mediated suppression of an oral-immune program during early squamous neoplastic evolution
Cancer Research · 2026-04-03
Abstract 4081: A multimodal single-cell atlas reveals a pathogenic epithelial-myeloid circuit driving HNSCC progression
Cancer Research · 2026-04-03
Targeting STAT3 Promotes Tumor Cell Death and Enhances T-Cell Activity in HPV16-Positive Cancer
Cancers · 2026-02-12
Supplementary file from Targeting RNA Exonuclease XRN1 Potentiates Efficacy of Cancer Immunotherapy
2025-11-24
Precision Epigenetic Reprogramming: CoREST Inhibition Sensitizes STK11-Mutant Tumors to Immune Checkpoint Blockade Therapy
Cancer Research · 2025-10-15 · 1 citations
A high-power spatial, single-cell view of pericytes in esophageal cancer metastasis
Nature Genetics · 2025-10-01
Unmasking cancer’s hidden nerve route with patient-derived organoids
Cell stem cell · 2025-10-01
ETS1 Orchestrates a Hybrid EMT Program Driving in vivo Metastasis and Immune EvasionPreprint
bioRxiv (Cold Spring Harbor Laboratory) · 2025-07-21
Supplementary Figure 5 from Genomic and Single-Cell Analyses Characterize Patient-Derived Tumor Organoids to Enable Personalized Therapy for Head and Neck Squamous Cell CarcinomaPreprint
2025-07-15
Supplementary Figure 6 from Genomic and Single-Cell Analyses Characterize Patient-Derived Tumor Organoids to Enable Personalized Therapy for Head and Neck Squamous Cell CarcinomaPreprint
2025-07-15
Supplementary Figure 3 from Genomic and Single-Cell Analyses Characterize Patient-Derived Tumor Organoids to Enable Personalized Therapy for Head and Neck Squamous Cell CarcinomaPreprint
2025-07-15
Supplementary Figure 7 from Genomic and Single-Cell Analyses Characterize Patient-Derived Tumor Organoids to Enable Personalized Therapy for Head and Neck Squamous Cell CarcinomaPreprint
2025-07-15
Supplementary Figure 8 from Genomic and Single-Cell Analyses Characterize Patient-Derived Tumor Organoids to Enable Personalized Therapy for Head and Neck Squamous Cell CarcinomaPreprint
2025-07-15
Supplementary Figure 4 from Genomic and Single-Cell Analyses Characterize Patient-Derived Tumor Organoids to Enable Personalized Therapy for Head and Neck Squamous Cell CarcinomaPreprint
2025-07-15
Supplementary Tables from Genomic and Single-Cell Analyses Characterize Patient-Derived Tumor Organoids to Enable Personalized Therapy for Head and Neck Squamous Cell Carcinoma
2025-07-15
Supplementary Figure 9 from Genomic and Single-Cell Analyses Characterize Patient-Derived Tumor Organoids to Enable Personalized Therapy for Head and Neck Squamous Cell CarcinomaPreprint
2025-07-15
Supplementary Figure 1 from Genomic and Single-Cell Analyses Characterize Patient-Derived Tumor Organoids to Enable Personalized Therapy for Head and Neck Squamous Cell CarcinomaPreprint
2025-07-15
Supplementary Figure 2 from Genomic and Single-Cell Analyses Characterize Patient-Derived Tumor Organoids to Enable Personalized Therapy for Head and Neck Squamous Cell CarcinomaPreprint
2025-07-15
Data from Genomic and Single-Cell Analyses Characterize Patient-Derived Tumor Organoids to Enable Personalized Therapy for Head and Neck Squamous Cell CarcinomaPreprint
2025-07-15

Open author page on OpenAlex →